Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

Mes dernières consult.
Most popular
Real-time Quote. Real-time Tradegate - 01/16 04:16:07 pm
104.47 EUR   -0.03%
01/11 Bayer raises higher than expected 1.8 billion euros from Covestro..
01/11 BAYER : Reduces Direct Stake in Covestro to 14.2%
01/11 BAYER : sells 10.4 percent stake in Covestro
News SummaryMost relevantAll newsSector newsTweets

Bayer : Erica Mann to leave Bayer effective March 31, 2018 ...

share with twitter share with LinkedIn share with facebook
share via e-mail
11/15/2017 | 08:40am CET

Leverkusen, November 15, 2017- The Supervisory Board of Bayer AG has appointed Heiko Schipper (48) to the Board of Management of Bayer AG effective March 1, 2018. He will succeed Erica Mann as the head of the Consumer Health Division, which is headquartered in Basel, Switzerland. Mann has announced that she does not intend to extend her contract, which was scheduled to run until December 31, 2018. As it has been possible to find a successor at an earlier date, Mann has asked the Supervisory Board to be able to hand over leadership of the Consumer Health business and leave the company effective March 31, 2018.

Schipper is Deputy Executive Vice President of Nestlé S.A. and a member of its Executive Board based in Vevey, Switzerland. He is Head of Nestlé Nutrition, the global leader in the infant nutrition category with sales of EUR 8.8 billion. He started his career as an international marketing trainee at Nestlé 21 years ago and held key management positions in Southeast Asia, Switzerland and China. He has held global responsibility for Nestlé's infant nutrition division since 2013. 'Heiko Schipper has extensive international experience in the consumer market. We are convinced that he will successfully lead Bayer's Consumer Health business,' said Werner Wenning, Chairman of the Supervisory Board of Bayer AG. Wenning thanked Erica Mann for her work in expanding the business in recent years. 'Bayer today is one of the leading companies in the self-medication market. Ms. Mann has contributed substantially to this development. We would like to wish her all the best for the future.'

Heiko Schipper was born on August 21, 1969, in Amsterdam, the Netherlands. He completed his Master in Business Economics at the Erasmus University in Rotterdam, the Netherlands. Starting in 1994, he acquired his first professional experience at Heineken. He joined Nestlé as an international marketing trainee in 1996, developing his career in sales and marketing management roles in Bangladesh and Indonesia and at the company's global headquarters in Switzerland. He then took up general management roles of increasing importance in the Philippines and, from 2007 to 2013, in the Greater China Region with the aim of developing Nestlé's position in this key market. In 2013, Schipper moved back to Switzerland to lead the global Infant Nutrition Division, a business with both consumer and medical characteristics. He was appointed to the Nestlé Group Executive Board in October 2014.

Heiko Schipper is a Dutch national. He is married and has three children.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 99,600 people and had sales of EUR 34.9 billion. Capital expenditures amounted to EUR 2.2 billion, R&D expenses to EUR 4.4 billion. For more information, go to www.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer AG published this content on 15 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 15 November 2017 07:39:01 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER
01/11 Bayer raises higher than expected 1.8 billion euros from Covestro placement
01/11 BAYER : Reduces Direct Stake in Covestro to 14.2%
01/11 BAYER : sells 10.4 percent stake in Covestro
01/10 Bayer to sell Covestro shares worth about $1.8 billion
01/10 BAYER : Further Reduces Stake in Covestro
01/10 BAYER : further reduces holding in Covestro
01/10 Bayer, J&J win reversal of US$28 million verdict in Xarelto lawsuit
01/10 BAYER : and Round Table on Responsible Soy renew cooperation
01/10 BAYER : J&J win reversal of $28 million verdict in Xarelto lawsuit
01/08 BAYER : inaugurates new greenhouse for insecticide research
More news
News from SeekingAlpha
01/15 ROAD TO FINANCIAL INDEPENDENCE : My December 88-Stock Portfolio Review
01/11 Bayer sells 10.4% stake in Covestro, raising ?1.8B
01/07 Rethinking Free Cash Flow
2017 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 26, 2017
2017 Britain's cost watchdog backs Novartis' MS med Extavia for use by NHS
Financials (€)
Sales 2017 36 021 M
EBIT 2017 7 716 M
Net income 2017 6 565 M
Debt 2017 8 839 M
Yield 2017 2,51%
P/E ratio 2017 13,58
P/E ratio 2018 18,26
EV / Sales 2017 2,64x
EV / Sales 2018 2,43x
Capitalization 86 416 M
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 122 €
Spread / Average Target 17%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER0.83%106 071
JOHNSON & JOHNSON4.32%391 587
NOVARTIS1.80%225 838
ROCHE HOLDING LTD.-0.28%218 350
PFIZER0.88%217 804